Second-Line CML Drug Evokes Faster Response, Fewer Side Effects

Second-Line CML Drug Evokes Faster Response, Fewer Side Effects
Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center.

Read more on Newswise